Plandai Biotech Stock Analysis
Plandai Biotech holds a debt-to-equity ratio of 0.95. Plandai Biotech's financial risk is the risk to Plandai Biotech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Plandai Biotech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Plandai Biotech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Plandai Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Plandai Biotech's stakeholders.
For many companies, including Plandai Biotech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Plandai Biotech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Plandai Biotech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Plandai Biotech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Plandai Biotech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Plandai Biotech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Plandai Biotech is said to be less leveraged. If creditors hold a majority of Plandai Biotech's assets, the Company is said to be highly leveraged.
Plandai Biotech is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Plandai Biotech pink sheet analysis is to determine its intrinsic value, which is an estimate of what Plandai Biotech is worth, separate from its market price. There are two main types of Plandai Biotech's stock analysis: fundamental analysis and technical analysis.
The Plandai Biotech pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Plandai |
Plandai Pink Sheet Analysis Notes
The company recorded a loss per share of 0.03. Plandai Biotech had not issued any dividends in recent years. The entity had 1:2000 split on the 19th of September 2008. Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. Planda Biotechnology, Inc. is based in London, the United Kingdom. Diamond Ranch is traded on OTC Exchange in the United States.The quote for Plandai Biotech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Plandai Biotech contact Roger BaylisDuffield at 44 91 7900 9829 or learn more at https://www.plandaibiotech.com.Plandai Biotech Investment Alerts
| Plandai Biotech is way too risky over 90 days horizon | |
| Plandai Biotech has some characteristics of a very speculative penny stock | |
| Plandai Biotech appears to be risky and price may revert if volatility continues | |
| Plandai Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 411.99 K. Net Loss for the year was (4.01 M) with loss before overhead, payroll, taxes, and interest of (768.91 K). | |
| Plandai Biotech currently holds about 7.96 K in cash with (1.1 M) of positive cash flow from operations. |
Plandai Biotech Thematic Classifications
In addition to having Plandai Biotech pink sheet in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | MarijuanaEntities with exposure to distribution of Marijuana | |
 | Disruptive TechnologiesFirms and ETFs that are involved or betting on industries or trends that are projected to experience exponential growth |
Plandai Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 276.35 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Plandai Biotech's market, we take the total number of its shares issued and multiply it by Plandai Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plandai Biotech, as well as the relationship between them.Plandai Biotech Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Moving Average is predictive technique used to analyze Plandai Biotech price data points by creating a series of averages of different subsets of Plandai Biotech entire price series.
Plandai Biotech Outstanding Bonds
Plandai Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Plandai Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Plandai bonds can be classified according to their maturity, which is the date when Plandai Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Plandai Biotech Debt to Cash Allocation
Many companies such as Plandai Biotech, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Plandai Biotech currently holds 50.53 K in liabilities with Debt to Equity (D/E) ratio of 0.95, which is about average as compared to similar companies. Plandai Biotech has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Plandai Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Plandai Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Plandai Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Plandai to invest in growth at high rates of return. When we think about Plandai Biotech's use of debt, we should always consider it together with cash and equity.Plandai Biotech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Plandai Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Plandai Biotech, which in turn will lower the firm's financial flexibility.Plandai Biotech Corporate Bonds Issued
About Plandai Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Plandai Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Plandai shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Plandai Biotech. By using and applying Plandai Pink Sheet analysis, traders can create a robust methodology for identifying Plandai entry and exit points for their positions.
Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. Planda Biotechnology, Inc. is based in London, the United Kingdom. Diamond Ranch is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Plandai Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Other Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.